Sobotka Glenn sold (to issuer) 11,793 shares of ASTH

Sobotka Glenn sold (to issuer) 11,793 shares of Astrana Health, Inc. (ASTH) on 2026-08-07.

Original reporting
SEC EDGAR · Sobotka Glenn
Published Aug 11, 2026, 9:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ASTH
Neutral
low confidence
Mentioned
$ASTH
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ASTHNeutralLow
01

Why it matters

The newest fact is the reported sale to the issuer of 11,793 shares by Sobotka Glenn, with holdings after transaction of 2,246 shares. No 10b5-1 plan is indicated and no price/value is provided.

02

Market read

Primarily a compliance disclosure; without disclosed price/value or a broader corporate catalyst, it is unlikely to drive a new trading thesis.

03

What to watch

Because the price and total value are not disclosed, traders cannot assess whether the sale was at favorable or unfavorable levels, reducing interpretability.

Relevance 3/10Novelty 2/10Timing: Filed 2026-08-11 after-hours; transaction dated 2026-08-07.

Background

This is an SEC Form 4 insider transaction disclosure for Astrana Health, Inc. (ASTH).

Company-level read

Ticker impact

$ASTHNeutralLow confidence
Context

Astrana Health (ASTH) disclosed an insider sale to the issuer of 11,793 shares by Sobotka Glenn on 2026-08-07 via Form 4.

Expected impact

Low likelihood of a sustained price move based solely on this Form 4.

Evidence & confidence

The filing is a Form 4 insider sale to the issuer (buyback participation style) with price/value not disclosed and no accompanying corporate event or guidance change.

Market effects

No clear sector read-through from a single routine insider sale.

None indicated.

None indicated.

Counterpoint

If the sale is part of a larger, undisclosed pattern of insider de-risking, it could modestly pressure sentiment, but this filing alone provides limited evidence.

Key entities

  • Astrana Health, Inc.

    Company subject of the Form 4 insider transaction disclosure (ASTH).

  • Sobotka Glenn

    Reporter of the Form 4 transaction, selling 11,793 shares to the issuer.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ASTHHighAI 8/10

Astrana Health Earnings Call Highlights Growth and Deleveraging

Astrana Health (ASTH) reported Q3 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). The company highlighted organic growth, debt reduction, and favorable Medicare trends. Management maintained full-year guidance, expecting revenue of $3.9B-$4B and adjusted EBITDA of $261M-$274M. Challenges include Medicaid pressure and seasonality.

$ASTHMed

Astrana Health 3Q 2026: Revenue $1.02B, EPS $0.26 — 10-Q Summary

Astrana Health reported 3Q 2026 revenue of $1.02B, up 7% YoY, and net income of $13.0M, compared to $373K last year. Growth was driven by 9% increase in capitation revenue. Care Partners saw 8% revenue growth and 94% operating income rise, while Care Delivery revenue increased 5% but operating loss widened. Care Enablement revenue rose 5% with 4% higher operating income. Astrana managed 29 IPAs and 1.5M patients as of September 30, 2026.

$ASTHMed

Astrana Health Inc (ASTH) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA

Astrana Health Inc (ASTH) reported Q3 2026 earnings, highlighting record revenue and EBITDA growth. CEO Brandon Sim discussed Medicaid membership attrition, Medicare Advantage dynamics, and care enablement business momentum. The company expects mid-teens EBITDA growth despite Medicaid headwinds. A cybersecurity incident is under investigation, and a new 'premiums at risk' disclosure was introduced for ACO business transparency.

$ASTHHighAI 8/10

Astrana Health (ASTH) Q3 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). Membership grew to 1.5M, with Medicare Advantage increasing organically. The company completed acquisitions and partnerships, expanding its presence. Medical cost trends were slightly better than expected, with Texas operations performing ahead of plan. Free cash flow reached $105M, and net leverage was reduced to 2.2x.

$ASTHMed

Astrana Health Q3 Earnings Call Highlights

Astrana Health reported 1.5 million members under management, with Medicare Advantage growth offsetting Medicaid attrition. The company expects Medicaid membership to decline 10-15% in 2027, impacting adjusted EBITDA. Medical cost trends were slightly better than expected, with Medicare Advantage margins stable. Astrana plans 82% of capitation revenue from full-risk arrangements by 2026 and completed acquisitions and partnerships.